Corbus Pharmaceuticals Holdings, Inc. — Income Charts
41 quarters of history · ending 2024-09-30 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+447.9% +$972K
$1M
R&D↑+65.0% +$4M
$11M
D&A↓-24.0% -$48K
$152K
Operating Income↓-63.4% -$6M
$-16M
EBITDA↓-65.3% -$6M
$-15M
Interest Expense↓-60.0% -$600K
$400K
Interest Income↓-97.2% -$436K
$13K
Net Income↓-37.1% -$4M
$-14M
Operating Margin↑+3068.3pts
-1304.0%
Net Margin↑+3473.5pts
-1159.2%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+0.4pts
5.9%
ETR Foreign Differential (pp)↑+1.4pts
-0.3%
Operating Lease Cost↓-0.2% -$473
$214K
Revenue YoY Variation↑+307.9pts
447.9%
Income YoY Variation↓-47.4pts
-63.4%
Revenue QoQ Variation↑+37.7pts
31.2%
Income QoQ Variation↓-25.2pts
-41.1%